IOncology

t the 2024 ESMO BC conference, Professor Hope S. Rugo, the recipient of the 2024 ESMO Breast Cancer Award, reflected on the current challenges in the field of breast cancer during her speech. After working in the field of malignant hematology for nine years, Professor Hope S. Rugo's mother was diagnosed with metastatic breast cancer, prompting her to transition to breast cancer research and clinical practice. It was a difficult time for cancer patients, with limited treatment options, unfocused care, poor management of side effects, and no end-of-life support. Today, Hope S. Rugo is a Professor of Medicine at the Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco (UCSF), and she has been awarded the 2024 ESMO Breast Cancer Award for her outstanding contributions to improving treatment options for future generations of breast cancer patients. Her desire to honor her mother has always been behind her professional achievements.

At the 2024 ESMO BC conference, new data from the TROPION-Breast01 study highlighted that notable adverse events were typically low-grade, manageable, and did not interfere with patients' expected treatment.

May 31, 2024Open Immersive ReaderEditor's Note: From April 19 to April 20, 2024, the 11th Sino-French (International) Advanced Breast Cancer Forum (SFBCS) was grandly held in Chongqing, where domestic and international experts shared vital content on basic breast cancer research, pathology diagnostics, surgical operations, and systemic treatment. In the surgical session, Professor Hongyuan Li from The First Hospital affiliated with Chongqing Medical University analyzed the "hot issues in subcutaneous mastectomy combined with breast reconstruction" based on his real-case follow-up experiences. "Oncology Frontier" took this opportunity to interview Professor Li on-site, providing guidance on breast reconstruction.

The 39th Annual European Association of Urology (EAU) Conference was grandly held from April 5th to 8th, 2024, in Paris, France. As a top-tier event in the global field of urology, the EAU Conference gathered numerous experts and scholars in the urology field to discuss cutting-edge advancements and future trends in urology. At this year's EAU Conference, Professor Qiang Wei and Professor Lu Yang's research team from West China Hospital of Sichuan University had multiple studies selected, representing the latest developments in urology in China and contributing significantly to the global advancement of urology. The "Oncology Frontier" magazine has compiled the relevant research below for readers' enjoyment.

FMS-like tyrosine kinase 3 (FLT3) mutations, particularly internal tandem duplication mutations (FLT3-ITD), are one of the significant factors affecting the prognosis of patients with acute myeloid leukemia (AML). Overcoming the challenge of relapse after transplantation in patients with FLT3-mutated AML remains a significant clinical hurdle. At the 50th European Bone Marrow Transplantation (EBMT) annual meeting, Professor Yanmin Zhao from The First Affiliated Hospital of Zhejiang University School of Medicine presented a study (Abstract No.: OS18-08), which explored the impact of mutations in myelodysplasia-related (MR) genes on maintenance treatment outcomes after transplantation for FLT3-ITD AML patients. "Oncology Frontier - Hematology Frontier" invited Professor Yanmin Zhao to share insights into the maintenance treatment strategies, challenges, and future research directions for FLT3-ITD mutant AML patients after transplantation.

Acute myeloid leukemia (AML) with t(8;21)(q22;q22.1) is one subtype among AML with recurrent genetic abnormalities, characterized by the translocation between chromosome 8q22 and chromosome 21q22. This translocation leads to the fusion of the RUNX1 gene on 8q22 with the RUNX1T1 gene on 21q22, forming the RUNX1-RUNX1T1 fusion gene. From April 14th to 17th, 2024, the 50th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) was held in Glasgow, UK. The conference focused on the latest advancements in stem cell transplantation and cell therapy, advancing towards better clinical outcomes for patients with hematologic diseases and blood tumors. In this congress, the team led by Yi Luo/Yibo Wu from The First Affiliated Hospital of Zhejiang University School of Medicine in China presented a clinical study, sharing the treatment status and prognosis of AML with t(8;21)(q22;q22.1). This journal is honored to invite Dr. Yibo Wu to share the research findings and their clinical significance with colleagues.

The 2024 CSCO Guideline Conference, co-hosted by the Chinese Society of Clinical Oncology (CSCO) and the Beijing Hope Science Clinical Oncology Research Foundation, took place in Jinan on April 26-27. At the event, Professor Jun Guo from Peking University Cancer Hospital was interviewed by "Oncology Frontier." He discussed significant updates in the new editions of the CSCO guidelines for urothelial carcinoma and melanoma, shared insights into the unique features of the CSCO guidelines, and provided an overview of the current and future states of anti-cancer drug development in China.

As time passes and seasons flow, we always embark on new journeys and endeavors through repeated reviews and outlooks. The annual review of the Northern Breast Cancer Salon and the discussion on the 2024 CSCO BC Guidelines update were held from January 5-6, 2024, in Beijing. "Oncology Frontier" specially interviewed Professor Rui Ge from East Hospital affiliated with Fudan University to reflect on the progress in breast cancer treatment i

The 2024 update of the Chinese Society of Clinical Oncology (CSCO) Guidelines for the Diagnosis and Treatment of Colorectal Cancer has been released. The new edition incorporates the latest evidence-based medical developments, adds new biomarkers for colorectal cancer, enriches clinical treatment strategy options, and adjusts the recommendation levels for various treatment protocols. Oncology Frontier interviewed Professor Ying Yuan from The Second Affiliated Hospital of Zhejiang University School of Medicine, one of the guideline's authors, to discuss the key updates and their clinical significance.

Transurethral resection of bladder tumor (TURBt) is the primary treatment for non-muscle-invasive bladder cancer (NMIBC), but the postoperative tumor recurrence rate remains high, posing a significant clinical challenge. To prevent tumor recurrence, different intravesical therapies are administered post-TURBt based on the patient's recurrence risk level. At the 2024 39th Annual European Association of Urology (EAU24) Congress, several studies focused on postoperative intravesical therapy strategies for NMIBC. Professor Fufu Zheng from The First Affiliated Hospital of Sun Yat-sen University provided a detailed analysis of these studies, exploring precise and individualized treatment strategies for NMIBC.